Clinical trials: HCC
Colon Cancer, Esophageal Carcinoma
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.
- Conditions
- Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer
- Trial name
- CARTEPC (NCT03013712)
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Hepatocellular Carcinoma (HCC)
Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
This study aims to address the issue of a lack of individualized basis for selecting liver resection (LH) or microwave ablation (MWA) in early-stage hepatocellular carcinoma (HCC) patients to reduce the early recurrence rate (≤2…
- Trial name
- HDL-CEUS-MRI (NCT07582419)
- Testing
- surgery, ablation
- Where
- China
- Volunteers
- 1,424 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma
Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with aggressive tumor behavior. Radiofrequency ablation (RFA) or microwave ablation (MWA) is an effective curative treatment for early stage HCC.
- Trial name
- NCT04555265
- Testing
- Radiofrequency ablation or microwave ablation
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver tumour and is the fourth leading cause of cancer-related death worldwide.
- Trial name
- NCT05359939
- Testing
- 18F-FDGal PET/CT versus 18F-choline PET/CT
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multicenter Phase Ib study to evaluate the effectiveness and safety of different doses of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have…
- Trial name
- NCT05363722
- Testing
- IBI310（0.5mg/kg）, IBI310（0.3mg/kg）, sintilimab
- Volunteers
- 80 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Cancer
Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
- Trial name
- FAC-L (NCT02482259)
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Hepatectomy, Hepatecellular Carcinoma
Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma
Selection criteria for safe hepatectomy for HCC are not well established. The aim of this study was the validation of the selection criteria for safe hepatectomy for hepatocellular carcinoma.
- Conditions
- Hepatectomy, Hepatecellular Carcinoma, Cirrhosis
- Trial name
- NCT02056041
- Testing
- Hepatectomy
- Where
- Italy
- Volunteers
- 336 people
- Sponsor
- University of Milan
Brain and Central Nervous System Tumors, Kidney Cancer
MT2004-30: Tomotherapy for Solid Tumors
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation…
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma
- Trial name
- NCT00623077
- Testing
- filgrastim, busulfan, etoposide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hepatocellular Carcinoma
Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography
This study aims to investigate the feasibility and accuracy of Multi-Detector CT angiography acquired before Trans-arterial Chemo-embolization (TACE) in detecting Hepato-cellular carcinoma feeding vessels compared to DSA…
- Trial name
- NCT05304572
- Testing
- Multi-Detector CT angiography, Trans-arterial chemoembolization and DSA
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma, Fibrolamellar Carcinoma
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.
- Trial name
- NCT05603572
- Testing
- KAT-101, KAT-201
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Primocure Pharma
Hepatocellular Carcinoma
Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers
The purpose of this study is to id transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular targeted therapies in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCEsub (NCT05278195)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma (HCC)
The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths in the world.
- Trial name
- NCT03138239
- Testing
- Ga-68-PSMA scan, and PET -CT F-18-FDG
- Volunteers
- 16 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatic Carcinoma, Chemoembolizaton
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
To evaluate the safety, advantages, and appropriateness of performing transarterial hepatic emobolization of liver cancer via arterial access from the radial artery versus conventional transfemoral arterial access.
- Conditions
- Hepatic Carcinoma, Chemoembolizaton, Transarterial Embolization
- Trial name
- ACCESS (NCT03163186)
- Testing
- Transarterial embolization
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Advanced Hepatocellular Carcinoma
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
- Trial name
- NCT05628545
- Testing
- GDKM-100 injection
- Where
- China
- Sponsor
- Guangdong GD Kongming Biotech LLC
Hepatocellular Carcinoma (HCC), Liver Ablation
International Study on Treatment of Liver (HCC) Patients With IRE
Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation
- Conditions
- Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult
- Trial name
- LIVERHCC-IRE (NCT07192731)
- Testing
- Irreversible Electroporation
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Angiodynamics, Inc.
Melanoma, Hepatocellular Carcinoma (HCC)
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
- Conditions
- Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H)
- Trial name
- NCT05909995
- Testing
- INCB 99280 with Ipilimumab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03722875
- Testing
- SHR-1210, apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Hepatocellular Carcinoma
Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients
To explore biomarkers predictive of clinical response to sorafenib in unresectable hepatocellular carcinoma using the Prometheus Platform To analyze expression and activation status of receptor tyrosine kinases in signal…
- Trial name
- NCT01481805
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with most patients developing HCC due to chronic liver diseases. Unfortunately, HCC has a morality to incidence ratio that approaches 1.
- Trial name
- NCT05738772
- Testing
- serum sample for ELIZA
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Sohag University